Remove society dementia
article thumbnail

Pushing technology and drugs to the limit in efforts to deal with dementia | Letters

The Guardian - Pharmaceutical Industry

Indeed, Alzheimer’s Society first funded Prof John Hardy’s amyloid research back in 1989, and it is only now that we are seeing the first amyloid-targeting treatments that show evidence of slowing the progression of Alzheimer’s disease. Continue reading.

43
article thumbnail

Pharma group seeks digital measure standards for Alzheimer’s

pharmaphorum

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias.

107
107
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Turning point for Alzheimer’s treatment as donanemab slows progress in early disease

Hospital Pharmacy Europe

Commenting on the research, Dr Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, said:  ‘This is truly a turning point in the fight against Alzheimer’s and science is proving that it is possible to slow down the disease. Donanemab and disease progression A total of 1,736 participants (57.4% Some 68.1%

article thumbnail

Will Your Diet Help You Avoid Dementia?

The People's Pharmacy

Now a study suggests that a modified Mediterranean diet might work even better to help you avoid dementia. However, the scientists concluded that a modified Mediterranean ketogenic diet seems more likely to help people avoid dementia. Genetic susceptibility also played a role in determining who was able to avoid dementia.

56
article thumbnail

Alzheimer’s blood test could help early diagnosis and direct treatment, research suggests

Hospital Pharmacy Europe

It raises the potential for early diagnosis to make best use of new medicines that slow the rate of cognitive decline but also could help doctors distinguish between different types of dementia in order to direct treatment. Of all the biomarkers currently being studied for diagnosing Alzheimer’s disease, this one has shown the best results.’

article thumbnail

Alzheimer’s disease statistics 2023

The Checkup by Singlecare

If you or someone you know is experiencing these troubles, it’s important to get them evaluated by a doctor as it could be a serious issue, like Alzheimer’s disease or related dementias. Simply put, Alzheimer’s disease is a type of dementia that affects older adults. million people in the United States will have Alzheimer’s dementia.

article thumbnail

After FDA nod, Eisai and Biogen file lecanemab in EU

pharmaphorum

The top-line readout from CLARITY-AD showed a 27% reduction in cognitive decline compared to placebo measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale. “The upcoming 10-year plan for dementia must prioritise boosting stagnant dementia diagnosis rates and preparing the NHS.”

FDA 52